Keytruda (pembrolizumab) has a half-life of about 22 days, meaning it takes roughly 4 to 5 months for the drug itself to clear from your bloodstream after your last infusion. But the effects on your immune system can persist much longer, sometimes a year or more, which is why side effects can still appear months after you stop treatment.
How Long the Drug Takes to Clear
Keytruda leaves your body gradually. With each half-life of approximately 22 days, the concentration in your blood drops by half. After five half-lives, a drug is considered essentially eliminated. For Keytruda, that math works out to about 110 days, or roughly 3.5 to 4 months. If you’ve been on treatment long enough to reach steady state (around 16 weeks of regular infusions), the starting concentration is higher due to accumulation, so clearance may take closer to 5 months from your final dose.
Your body clears Keytruda at a rate of about 195 mL per day at steady state, and the drug distributes into a relatively small volume of about 6 liters, mostly staying in the bloodstream rather than spreading deeply into tissues. This is typical for antibody-based drugs, which are large molecules broken down slowly by the body’s normal protein recycling processes rather than filtered through the liver or kidneys like most traditional medications.
Immune Effects Last Longer Than the Drug
Here’s the important distinction: the drug leaving your blood is not the same as the drug’s effects wearing off. Keytruda works by blocking a receptor called PD-1 on your immune cells, essentially removing a brake that was keeping those cells from attacking cancer. Studies of similar checkpoint inhibitors show that a single dose can keep PD-1 receptors occupied on T cells for up to 100 days. After months of regular infusions, that receptor blockade doesn’t just vanish the moment drug levels drop below a detectable threshold.
Your immune system, once “unleashed” by Keytruda, can remain in a heightened state for many months. The T cells that were activated during treatment continue to function, and the immune memory created during therapy persists independently of the drug itself. This is actually part of why Keytruda works against cancer: it creates a durable immune response that can outlast the treatment period. But it also means the potential for immune-related side effects extends well beyond your last infusion.
Side Effects Can Appear Months Later
One of the most important things to understand about Keytruda’s timeline is that new side effects can surface long after you stop treatment. Researchers have documented what they call delayed immune-related events, defined as new immune side effects appearing 90 days or more after the last dose. In published case series, the median time to diagnosis of these delayed events was 6 months after stopping immunotherapy, with some cases emerging as late as 28 months out.
These delayed reactions happen because Keytruda’s mechanism of action is fundamentally different from chemotherapy. Chemotherapy drugs are toxic to cells directly, and once they’re gone, so is the toxicity. Keytruda reprograms your immune system’s behavior. That reprogramming doesn’t have a clean off switch. Your immune cells may continue to be overactive against normal tissues (causing inflammation in the thyroid, liver, lungs, skin, or other organs) well after the drug itself has been eliminated.
The most common delayed effects involve the endocrine system, particularly the thyroid. Thyroid dysfunction that begins during treatment can become permanent, requiring ongoing hormone replacement. Other organs can also be affected late, including the joints, skin, and gut. If you develop new symptoms in the months after stopping Keytruda, your treatment history with immunotherapy is relevant information for any doctor you see, even if it’s been a year or more.
Factors That Affect Clearance Speed
Not everyone clears Keytruda at exactly the same rate. Population studies have identified several factors that influence how quickly the drug leaves your system. Body weight plays a moderate role: heavier patients tend to clear the drug somewhat faster in absolute terms, though the relationship isn’t perfectly linear. Sex, kidney function, baseline albumin levels (a protein in your blood), overall health status, tumor burden, and the type of cancer being treated all contribute to individual variation.
That said, the practical differences between patients are modest. The half-life of 22 days has a coefficient of variation around 32%, meaning most people fall in a range of roughly 15 to 29 days. Even at the extremes, the difference between a fast and slow metabolizer amounts to a few weeks, not months. For most practical purposes, you can assume the drug is gone from your blood within 4 to 5 months of your last infusion regardless of your individual characteristics.
What This Means for Starting New Treatments
If you’re stopping Keytruda and moving to a different treatment, you might expect a strict waiting period before you can begin something new. The reality is more nuanced. Major oncology organizations have moved away from rigid washout periods based purely on half-life calculations. Current recommendations from groups like ASCO emphasize that readiness for a new treatment should be based on whether you’ve recovered from any active side effects, not on hitting a specific number of days since your last dose.
For clinical trials, the older approach of requiring a set number of half-lives to pass is increasingly seen as outdated. Instead, trial protocols are encouraged to assess patients based on clinical and laboratory markers: Are your liver enzymes normal? Has any active inflammation resolved? Are you off immunosuppressive medications used to manage side effects? The general timeframe for resolution of most immune-related side effects is around 12 weeks, though this varies considerably depending on which organs were affected and how severely.
If you’re transitioning to a new cancer therapy or considering a clinical trial, your oncologist will evaluate your specific situation rather than simply counting days from your last Keytruda infusion. The lingering immune effects matter more than the drug concentration itself, because those effects determine both your risk of overlapping toxicity with a new treatment and your baseline organ function going into the next phase of care.